RxDoctor Payments Data

Albert Gros, MD

Interventional Pain Medicine · Opelousas, LANPI 1457395832

Payments from drug & device makers

What this record shows

16 manufacturers reported payments, led by Boston Scientific at 41.6% of the total. Reporting peaked in 2022 at $3,366 and has fallen 78.4% since, to $727 in 2025.

$8,116in general payments, 2019–2025

Across 109 payments — averaging $74.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Abbott$1K
  • Pacira Pharmaceuticals Incorporated$1K
  • Stryker$1K
  • VGI Medical, LLC$267
  • Spinal Simplicity, LLC$170
  • plus $833 from 10 others

What the payments were for

  • Travel & lodging$3,36641%
  • Food & beverage$4,75059%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,116 in reported general payments places this provider in the 65th percentile of 57 interventional pain medicine providers in Louisiana.

See all interventional pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$382,987
Medicare patients
452
Services billed
9,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen754$17,578
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen371$11,509
Xtampza ErOxycodone Myristate12$11,063
Oxycodone Hcl509$10,450
Gabapentin350$3,690
Tizanidine Hcl361$2,471
Morphine Sulfate ErMorphine Sulfate87$1,539
Cyclobenzaprine Hcl197$1,138
Tramadol Hcl106$1,053
Diclofenac Sodium73$993
Pregabalin68$932
Hydromorphone Hcl27$537
Morphine Sulfate14$527
Methocarbamol79$487
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine20$378

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Opelousas

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →